However, the severe off-target toxicity of the engineered T cells is a primary concern of its application in the clinic, suggesting that safety and efficacy must be considered in targeting AFP-based HCC immunotherapy (9, 27–29). The gene discussed is AFP; the disease is hepatocellular carcinoma.